Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNLIMITED: Sibutramine/Topiramate FDC for Obesity
NCT05209984Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sibutramine, topiramate in obesity, sponsored by Eurofarma. Planned start Apr 2026; status: withdrawn.
02
Drugs
sibutraminetopiramate
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05209984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05209984.